BMS alum Catherine Owen Adams to lead Acadia

Catherine Owen Adams has succeeded Steve Davis as CEO of  Acadia Pharmaceuticals Inc. (NASDAQ:ACAD) and joined the commercial neuroscience company’s board. Most recently, Owen Adams was SVP and GM, U.S., at Bristol Myers Squibb Co. (NYSE:BMY). She led a $20 billion commercial business that comprised drugs for oncology, cardiovascular and immunology indications with more than 3,000 employees.

Boston-based Bambusa Therapeutics Inc. hired René van der Merwe as CMO, van der Merwe and Bambusa CEO Shanshan Xu announced on LinkedIn. Van der Merwe was CMO at Aiolos Bio Inc.; she also was VP of respiratory at MedImmune, the biologics unit of AstraZeneca plc (LSE:AZN; NASDAQ:AZN). Bambusa, which is developing bispecific antibodies for immune and inflammatory disorders, launched this month with a $15 million seed round from BVF Partners, KKR-backed Dawn Biopharma, Salvia GmbH and INCE Capital. ...